DRL-Header DRL-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Canakinumab

            Therapeutic Area: Rare Diseases and Disorders Product Name: Ilaris

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2021


            This new indication follows the existing approval of Ilaris for Systemic Juvenile Idiopathic Arthritis (SJIA)1, now allowing patients over the age of 16 to be treated. Ilaris is an interleukin-1 beta inhibitor that provides a new mode of treatment for this disease.